{
    "hands_on_practices": [
        {
            "introduction": "The journey of any virus begins with a specific molecular \"handshake\" between a viral protein and a host cell receptor. This exercise quantifies this crucial first step for Hepatitis B Virus, focusing on the interaction between its preS1 domain and the hepatocyte's NTCP receptor. By applying fundamental principles of chemical equilibrium, you will calculate the receptor occupancy, providing a tangible measure of how effectively the virus can latch onto a target cell, which is the gateway to establishing infection.",
            "id": "4637545",
            "problem": "Hepatitis B virus (HBV) entry into hepatocytes is initiated when the preS1 domain of the large hepatitis B surface antigen binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor. Consider a monovalent receptor–ligand system at equilibrium on the hepatocyte surface, where the preS1–NTCP interaction is characterized by the equilibrium dissociation constant $K_{d}$. The receptor–ligand equilibrium follows mass-action kinetics, and the equilibrium dissociation constant is defined by $K_{d} = \\frac{[R][L]}{[RL]}$, where $[R]$ is the concentration of unbound receptor, $[L]$ is the concentration of free ligand, and $[RL]$ is the concentration of receptor–ligand complex. The total receptor concentration is $[R]_{\\text{tot}} = [R] + [RL]$, and the receptor occupancy (fraction of receptors bound by ligand) is $\\theta = \\frac{[RL]}{[R]_{\\text{tot}}}$.\n\nA hepatocyte is exposed to a preS1-lipopeptide inoculum at a free ligand concentration $[L] = 50\\,\\mathrm{nM}$. The preS1–NTCP equilibrium dissociation constant is measured to be $K_{d} = 5\\,\\mathrm{nM}$. Under the assumption that ligand is not substantially depleted by binding (so that $[L]$ is well-approximated by the bulk value) and that binding is one-to-one without cooperativity, derive $\\theta$ from the fundamental definitions above and compute its value for the given parameters. Express your final answer as a dimensionless decimal fraction rounded to four significant figures.",
            "solution": "The user has provided a problem statement that must first be validated for scientific soundness, well-posedness, and objectivity.\n\n### Step 1: Extract Givens\n- The system is a monovalent receptor-ligand interaction at equilibrium on a hepatocyte surface (preS1 domain of HBV and NTCP receptor).\n- The equilibrium dissociation constant is defined as $K_{d} = \\frac{[R][L]}{[RL]}$.\n- $[R]$ is the concentration of unbound receptor.\n- $[L]$ is the concentration of free ligand.\n- $[RL]$ is the concentration of receptor–ligand complex.\n- The total receptor concentration is defined as $[R]_{\\text{tot}} = [R] + [RL]$.\n- The receptor occupancy is defined as $\\theta = \\frac{[RL]}{[R]_{\\text{tot}}}$.\n- The free ligand concentration is given as $[L] = 50\\,\\mathrm{nM}$.\n- The equilibrium dissociation constant is given as $K_{d} = 5\\,\\mathrm{nM}$.\n- Assumption 1: $[L]$ is constant (ligand is not significantly depleted).\n- Assumption 2: Binding is one-to-one without cooperativity.\n- The objective is to first derive an expression for $\\theta$ from the provided definitions and then calculate its numerical value, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated against the validation criteria.\n\n- **Scientifically Grounded**: The problem is firmly rooted in the principles of chemical kinetics and receptor theory, specifically the law of mass action applied to a reversible bimolecular reaction. The biological context, the interaction between the HBV preS1 domain and the hepatocyte NTCP receptor, is a well-documented and fundamental step in viral entry. The concepts of equilibrium dissociation constant ($K_d$), receptor occupancy ($\\theta$), and the mass balance equations are standard in biochemistry and pharmacology. The provided values for $K_d$ and $[L]$ are realistic for such biological interactions. The problem is scientifically sound.\n- **Well-Posed**: All necessary variables, constants, and definitions ($K_d$, $[R]_{\\text{tot}}$, $\\theta$) are explicitly provided. The assumptions of constant ligand concentration and one-to-one binding are clearly stated, which ensures the problem is self-contained and leads to a single, unique solution. The goal is clearly defined.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language. There are no subjective elements or ambiguities.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is a standard exercise in biochemical equilibrium and poses a well-defined question based on sound scientific principles. The solution process may now proceed.\n\n---\n\nThe objective is to derive an expression for the receptor occupancy, $\\theta$, and then calculate its value. The derivation will begin from the fundamental definitions provided.\n\nThe receptor occupancy, $\\theta$, is defined as the fraction of total receptors that are bound by the ligand:\n$$\n\\theta = \\frac{[RL]}{[R]_{\\text{tot}}}\n$$\nThe total receptor concentration, $[R]_{\\text{tot}}$, is the sum of the concentrations of unbound (free) receptors, $[R]$, and ligand-bound receptors, $[RL]$:\n$$\n[R]_{\\text{tot}} = [R] + [RL]\n$$\nSubstituting this definition into the expression for $\\theta$ yields:\n$$\n\\theta = \\frac{[RL]}{[R] + [RL]}\n$$\nTo express $\\theta$ in terms of the free ligand concentration, $[L]$, and the equilibrium dissociation constant, $K_{d}$, we must find an expression for $[R]$ in terms of these parameters. The equilibrium dissociation constant is defined as:\n$$\nK_{d} = \\frac{[R][L]}{[RL]}\n$$\nThis equation describes the balance between the dissociation of the receptor-ligand complex and its formation at equilibrium. We can rearrange this expression to solve for the concentration of unbound receptors, $[R]$:\n$$\n[R] = \\frac{K_{d} [RL]}{[L]}\n$$\nNow, we substitute this expression for $[R]$ back into the equation for $\\theta$:\n$$\n\\theta = \\frac{[RL]}{\\left(\\frac{K_{d} [RL]}{[L]}\\right) + [RL]}\n$$\nThe term $[RL]$ is common to all terms in the fraction and can be factored out from the denominator:\n$$\n\\theta = \\frac{[RL]}{[RL] \\left(\\frac{K_{d}}{[L]} + 1\\right)}\n$$\nAssuming $[RL] \\neq 0$ (i.e., some binding occurs), we can cancel the $[RL]$ term from the numerator and denominator:\n$$\n\\theta = \\frac{1}{\\frac{K_{d}}{[L]} + 1}\n$$\nTo simplify this complex fraction, we can find a common denominator for the terms in the denominator of the main fraction:\n$$\n\\theta = \\frac{1}{\\frac{K_{d} + [L]}{[L]}}\n$$\nFinally, inverting the denominator gives the derived expression for receptor occupancy:\n$$\n\\theta = \\frac{[L]}{[L] + K_{d}}\n$$\nThis is the required expression for $\\theta$ derived from the fundamental definitions. This is a form of the Hill-Langmuir equation for a system with a Hill coefficient of $1$, consistent with the assumption of non-cooperative, one-to-one binding.\n\nWith the derived formula, we can now compute the numerical value of $\\theta$ using the given parameters: $[L] = 50\\,\\mathrm{nM}$ and $K_{d} = 5\\,\\mathrm{nM}$.\n$$\n\\theta = \\frac{50\\,\\mathrm{nM}}{50\\,\\mathrm{nM} + 5\\,\\mathrm{nM}}\n$$\nThe units of concentration ($\\mathrm{nM}$) cancel out, confirming that $\\theta$ is a dimensionless quantity as expected for a fraction.\n$$\n\\theta = \\frac{50}{55}\n$$\nThis fraction simplifies to:\n$$\n\\theta = \\frac{10}{11}\n$$\nTo express this as a decimal fraction rounded to four significant figures, we perform the division:\n$$\n\\theta = 0.90909090...\n$$\nThe first four significant figures are $9$, $0$, $9$, and $0$. The fifth significant figure is $9$, which is greater than or equal to $5$, so we must round up the fourth significant figure.\n$$\n\\theta \\approx 0.9091\n$$\nThus, under the given conditions, approximately $90.91\\%$ of the NTCP receptors on the hepatocyte surface are occupied by the preS1-lipopeptide.",
            "answer": "$$\n\\boxed{0.9091}\n$$"
        },
        {
            "introduction": "Once inside a hepatocyte, the HBV genome's fate determines the course of chronic infection, existing as either a stable, replication-driving minichromosome (cccDNA) or as fragments integrated into the host's own DNA. This thought experiment challenges you to act as a molecular detective, using the Central Dogma and core facts about the HBV life cycle to deduce the distinct biological roles of these two DNA forms. Mastering this distinction is essential for understanding the persistence of chronic HBV and the specific targets of antiviral therapies.",
            "id": "4637537",
            "problem": "A liver cell infected by hepatitis B virus (HBV) contains two possible viral DNA forms with distinct biological properties: covalently closed circular DNA (cccDNA) and integrated HBV DNA. Consider the following thought experiment in which a researcher isolates two hepatocyte populations. In population $X$, HBV persists as cccDNA but no integrated HBV sequences are detectable. In population $Y$, HBV sequences are integrated into host chromosomes, but cccDNA is undetectable. The researcher measures three outputs in each population under baseline conditions and after exposure to a nucleos(t)ide analog that inhibits the HBV polymerase: virion production $V$, pregenomic RNA $g$, and hepatitis B surface antigen $S$.\n\nUsing only the Central Dogma of Molecular Biology (DNA $\\rightarrow$ RNA $\\rightarrow$ protein) and the well-tested observation that hepadnaviruses replicate their genome via reverse transcription of pregenomic RNA inside nucleocapsids (executed by the viral polymerase that is the target of nucleos(t)ide analogs), which option best differentiates cccDNA from integrated HBV DNA across structure, replication competency, and susceptibility to nucleos(t)ide analogs?\n\nA. cccDNA exists as an episomal covalently closed circular minichromosome in the nucleus, templates all viral transcripts including pregenomic RNA $g$, and supports production of complete virions; nucleos(t)ide analogs that inhibit the viral polymerase markedly reduce $V$ but do not eradicate cccDNA or silence host polymerase activity on surface antigen $S$. Integrated HBV DNA consists of linear HBV fragments inserted into host chromosomes, is generally replication-incompetent for virion production, can produce $S$ via host RNA polymerase, and is not directly affected by nucleos(t)ide analogs that target the viral polymerase.\n\nB. cccDNA is a linearized HBV genome that integrates into host DNA and is the principal driver of $S$ only; nucleos(t)ide analogs directly degrade cccDNA and thereby eliminate $S$, whereas integrated HBV DNA remains episomal, is fully replication-competent, and produces complete virions.\n\nC. Both cccDNA and integrated HBV DNA are equally replication-competent sources of complete virions; nucleos(t)ide analogs primarily act by inhibiting host RNA polymerase and therefore reduce both $g$ and $S$ from either form while leaving $V$ unchanged.\n\nD. cccDNA is transcribed solely by the viral polymerase, so nucleos(t)ide analogs inhibit $g$ and $S$ from cccDNA; integrated HBV DNA is transcribed by host RNA polymerase, produces complete virions, and is more sensitive to nucleos(t)ide analogs than cccDNA because it relies on host polymerase function.",
            "solution": "The problem statement will be validated by first extracting the givens and then assessing its scientific validity and logical consistency.\n\n**Step 1: Extract Givens**\n- Two forms of Hepatitis B Virus (HBV) DNA in an infected liver cell: covalently closed circular DNA (cccDNA) and integrated HBV DNA.\n- These forms have distinct biological properties.\n- Population $X$: Hepatocytes with HBV as cccDNA only; no integrated HBV sequences.\n- Population $Y$: Hepatocytes with integrated HBV sequences only; no cccDNA.\n- Measured outputs: virion production ($V$), pregenomic RNA ($g$), and hepatitis B surface antigen ($S$).\n- A nucleos(t)ide analog that inhibits the HBV polymerase is used for treatment.\n- The analysis must be based on two principles:\n    1. The Central Dogma of Molecular Biology: DNA $\\rightarrow$ RNA $\\rightarrow$ protein.\n    2. Hepadnavirus replication mechanism: genome replication occurs via reverse transcription of pregenomic RNA ($g$) inside nucleocapsids, a process executed by the viral polymerase.\n- The question asks to identify the option that best differentiates cccDNA from integrated HBV DNA based on structure, replication competency, and susceptibility to nucleos(t)ide analogs.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Soundness:** The problem is grounded in established principles of molecular virology, specifically regarding the life cycle of HBV. The existence and distinct roles of cccDNA and integrated HBV DNA are central concepts in HBV pathogenesis. The description of hepadnavirus replication via reverse transcription, the function of pregenomic RNA, and the mechanism of action of nucleos(t)ide analogs as inhibitors of the viral reverse transcriptase (polymerase) are all factually correct and form the basis of current antiviral therapy for HBV.\n- **Well-Posedness:** The problem poses a clear question based on a well-defined hypothetical experiment. The two populations, $X$ and $Y$, serve to isolate the biological functions of cccDNA and integrated DNA, respectively. The givens—the Central Dogma and the HBV replication mechanism—provide a complete and sufficient logical framework to deduce the expected outcomes for $V$, $g$, and $S$ in each population, with and without the inhibitor. This structure allows for a unique and meaningful solution.\n- **Objectivity:** The problem is stated in precise, objective, and technical language standard to the fields of molecular biology and virology. It is free from ambiguity, subjectivity, or opinion.\n- **Flaw Analysis:**\n    - The problem does not violate any fundamental scientific laws.\n    - It is not metaphorical or irrelevant to its stated topic.\n    - The setup is logically consistent and complete for the task at hand. The idealized separation of cccDNA and integrated DNA into two populations is a valid construct for a thought experiment designed to test conceptual understanding.\n    - The scenario is scientifically plausible and does not contain any contradictions.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A solution will be derived by applying the given principles.\n\n**Derivation of Solution**\n\nLet us analyze the biological consequences for each population based on the provided principles.\n\n**Population $X$: cccDNA only**\n1.  **Structure and Transcription:** cccDNA is an episomal, non-integrated, stable circular DNA molecule residing in the host cell nucleus. According to the Central Dogma (DNA $\\rightarrow$ RNA), this DNA serves as a template for transcription. This process is carried out by the host cell's RNA polymerase II, which synthesizes all viral RNAs. These include:\n    - Pregenomic RNA ($g$): A greater-than-genome-length transcript that serves as the template for reverse transcription and also as the mRNA for the core protein and the viral polymerase.\n    - Subgenomic mRNAs: Transcripts that are translated to produce other viral proteins, such as the hepatitis B surface antigen ($S$).\n    - Therefore, in population $X$, we expect production of both $g$ and $S$.\n2.  **Replication and Virion ($V$) Production:** The problem states that replication proceeds by reverse transcription of $g$ via the viral polymerase. This process occurs within newly formed nucleocapsids. The newly synthesized DNA genome is then packaged into mature virions ($V$) which are subsequently released from the cell. Since population $X$ has cccDNA, which templates $g$, it is fully replication-competent. Therefore, population $X$ will produce virions ($V > 0$).\n3.  **Effect of Nucleos(t)ide Analog (NA):** The NA inhibits the HBV polymerase, which is a reverse transcriptase. This directly blocks the synthesis of new viral DNA from the $g$ template. Consequently, the formation of new DNA-containing nucleocapsids ceases, and virion production ($V$) will be markedly reduced. However, the NA does not affect the host RNA polymerase. Thus, transcription of the stable cccDNA template to produce $g$ and mRNA for $S$ will continue. The cccDNA molecule itself is not degraded or targeted by the NA.\n\n**Population $Y$: Integrated HBV DNA only**\n1.  **Structure and Transcription:** Integrated HBV DNA consists of linear viral DNA fragments inserted into the host chromosomes. As part of the host genome, it is transcribed by the host's RNA polymerase II. However, due to frequent fragmentation and rearrangement during the integration process, these sequences are typically unable to produce the full-length pregenomic RNA ($g$) required for replication. They are, however, often capable of producing subgenomic mRNAs, particularly the mRNA for the surface antigen ($S$). Therefore, in population $Y$, we expect production of $S$ but not functional $g$.\n2.  **Replication and Virion ($V$) Production:** Since population $Y$ cannot produce the full-length pregenomic RNA ($g$), the template for reverse transcription is absent. Without $g$, the replication cycle cannot be completed. Therefore, population $Y$ is replication-incompetent and will not produce complete virions ($V=0$).\n3.  **Effect of Nucleos(t)ide Analog (NA):** The NA inhibits the viral polymerase. Since population $Y$ is not undergoing active replication, the viral polymerase is not active, and thus the NA has no process to inhibit. The production of $S$ is dependent on transcription by the host RNA polymerase from the integrated DNA template, neither of which is affected by the NA. Therefore, the NA will have no effect on this population; $S$ production will continue, and $V$ will remain at zero.\n\n**Evaluation of Options**\n\n- **Option A:**\n  - \"cccDNA exists as an episomal covalently closed circular minichromosome in the nucleus, templates all viral transcripts including pregenomic RNA $g$, and supports production of complete virions\" - **Correct**. This accurately describes the structure and function of cccDNA.\n  - \"nucleos(t)ide analogs that inhibit the viral polymerase markedly reduce $V$ but do not eradicate cccDNA or silence host polymerase activity on surface antigen $S$.\" - **Correct**. This correctly describes the effect of NAs on the cccDNA-driven life cycle.\n  - \"Integrated HBV DNA consists of linear HBV fragments inserted into host chromosomes, is generally replication-incompetent for virion production, can produce $S$ via host RNA polymerase, and is not directly affected by nucleos(t)ide analogs that target the viral polymerase.\" - **Correct**. This accurately describes the structure, function, and drug susceptibility of integrated HBV DNA.\n  - **Verdict**: Every statement in this option aligns perfectly with the deductions from first principles. **Correct**.\n\n- **Option B:**\n  - \"cccDNA is a linearized HBV genome that integrates into host DNA\" - **Incorrect**. This incorrectly defines cccDNA; it describes integrated DNA. cccDNA is circular and episomal.\n  - The remainder of the option is based on this false premise, swapping the roles and properties of cccDNA and integrated DNA. For example, it claims integrated DNA is episomal and replication-competent.\n  - **Verdict**: This option contains multiple fundamental errors regarding the nature of the two DNA forms. **Incorrect**.\n\n- **Option C:**\n  - \"Both cccDNA and integrated HBV DNA are equally replication-competent sources of complete virions\" - **Incorrect**. A key distinction is that integrated DNA is generally replication-incompetent.\n  - \"nucleos(t)ide analogs primarily act by inhibiting host RNA polymerase\" - **Incorrect**. The problem states, correctly, that they inhibit the *HBV polymerase* (a reverse transcriptase).\n  - \"reduce both $g$ and $S$ from either form while leaving $V$ unchanged\" - **Incorrect**. This inverts the actual effect. NAs reduce $V$ by inhibiting reverse transcription, but do not directly affect transcription of $g$ and $S$.\n  - **Verdict**: This option mischaracterizes the competency of integrated DNA, the drug target, and the outcome of the inhibition. **Incorrect**.\n\n- **Option D:**\n  - \"cccDNA is transcribed solely by the viral polymerase\" - **Incorrect**. Transcription of DNA to RNA is performed by an RNA polymerase. In the nucleus, this is the host's enzyme. The viral polymerase is a reverse transcriptase (an RNA-dependent DNA polymerase).\n  - \"so nucleos(t)ide analogs inhibit $g$ and $S$ from cccDNA\" - **Incorrect**. This is a false conclusion from a false premise. NAs do not inhibit transcription from cccDNA.\n  - \"integrated HBV DNA ... produces complete virions\" - **Incorrect**. It is replication-incompetent.\n  - **Verdict**: This option fundamentally confuses the roles of the host RNA polymerase and the viral DNA polymerase/reverse transcriptase. **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "How does activity within billions of infected liver cells translate to the viral load measured in a patient's blood? This practice uses a classic pharmacokinetic model to bridge the microscopic world of viral production with the macroscopic, clinically-relevant outcome of viremia. By balancing the rates of viral production and clearance at steady state, you will calculate the proportion of the liver that must be infected to sustain a specific viral load, demonstrating how quantitative reasoning helps us understand systemic disease burden.",
            "id": "4637561",
            "problem": "A chronic Hepatitis B virus (HBV) infection is modeled as follows. Infected hepatocytes continuously produce virions, and virions are cleared from the circulation by first-order processes. Assume a single well-mixed plasma compartment. Let the measured mean serum HBV deoxyribonucleic acid (DNA) concentration be $C_s$ (viral copies per milliliter), the plasma volume be $V_p$ (liters), the total number of hepatocytes in the liver be $H$ (cells), the per-infected-cell virion production rate be $p$ (virions per cell per day), and the virion clearance rate constant be $c$ (per day). Assume steady state, so that the total rate of virion production equals the total rate of virion clearance in the plasma compartment. Also assume that the fraction of hepatocytes infected is $f$, so the number of infected hepatocytes is $fH$. Take $1$ liter $=$ $10^{3}$ milliliters.\n\nUsing only conservation of mass at steady state and the definitions above, determine the decimal fraction $f$ required to maintain the following measured equilibrium:\n\n- Serum HBV DNA concentration $C_s = 1.5 \\times 10^{7}$ viral copies per milliliter.\n- Plasma volume $V_p = 3.0$ liters.\n- Total hepatocytes $H = 2.5 \\times 10^{11}$ cells.\n- Per-infected-cell production $p = 1.0 \\times 10^{3}$ virions per cell per day.\n- Virion clearance rate $c = 0.70$ per day.\n\nExpress your final result as a unitless decimal fraction and round to three significant figures. Do not convert the fraction to a percentage.",
            "solution": "The problem is evaluated for validity prior to attempting a solution.\n\n**Step 1: Extract Givens**\n- Measured mean serum HBV DNA concentration: $C_s = 1.5 \\times 10^{7}$ viral copies per milliliter.\n- Plasma volume: $V_p = 3.0$ liters.\n- Total number of hepatocytes in the liver: $H = 2.5 \\times 10^{11}$ cells.\n- Per-infected-cell virion production rate: $p = 1.0 \\times 10^{3}$ virions per cell per day.\n- Virion clearance rate constant: $c = 0.70$ per day.\n- Fraction of hepatocytes infected: $f$.\n- Number of infected hepatocytes: $fH$.\n- Unit conversion: $1$ liter = $10^{3}$ milliliters.\n- Governing condition: At steady state, the total rate of virion production equals the total rate of virion clearance.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using a standard single-compartment model common in virology and pharmacology. It is well-posed, providing all necessary parameters to solve for a single unknown variable, $f$. The language is objective and the definitions are precise. The given numerical values are within plausible biological ranges for a chronic HBV infection. The problem is self-contained and logically consistent.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A solution will be derived.\n\nThe core principle of the model is that at steady state, the system is in equilibrium. This means the rate of virions being produced and entering the plasma compartment is equal to the rate of virions being cleared from it. This can be expressed as an equation:\n$$\nR_{\\text{production}} = R_{\\text{clearance}}\n$$\n\nFirst, we formulate the total virion production rate, $R_{\\text{production}}$. The problem states that there are $H$ total hepatocytes and a fraction $f$ of them are infected. Therefore, the number of infected hepatocytes is $fH$. Each of these infected cells produces new virions at a rate $p$. The total production rate is the product of the number of infected cells and the per-cell production rate:\n$$\nR_{\\text{production}} = (fH) \\cdot p\n$$\nThe units of this expression are (unitless) $\\times$ (cells) $\\times$ (virions / (cell $\\cdot$ day)), resulting in units of virions/day.\n\nNext, we formulate the total virion clearance rate, $R_{\\text{clearance}}$. The problem describes clearance as a first-order process with a rate constant $c$. This means the clearance rate is proportional to the total number of virions in the plasma, $N_{\\text{total}}$.\n$$\nR_{\\text{clearance}} = c \\cdot N_{\\text{total}}\n$$\nThe total number of virions, $N_{\\text{total}}$, is the product of the viral concentration, $C_s$, and the total plasma volume. A unit conversion is necessary, as $C_s$ is given in viral copies per milliliter and $V_p$ is in liters. Let the conversion factor be $k = 10^3$ milliliters/liter.\nThe total plasma volume in milliliters is $V_p \\cdot k$.\nThus, the total number of virions is:\n$$\nN_{\\text{total}} = C_s \\cdot (V_p \\cdot k) = C_s V_p \\cdot 10^3\n$$\nSubstituting this into the clearance rate equation:\n$$\nR_{\\text{clearance}} = c \\cdot (C_s V_p \\cdot 10^3)\n$$\nThe units of this expression are (day$^{-1}$) $\\times$ (virions / milliliter) $\\times$ (liters) $\\times$ (milliliters / liter), resulting in units of virions/day. The units for production and clearance rates are consistent.\n\nNow, we equate the production and clearance rates to represent the steady-state condition:\n$$\nf H p = c C_s V_p \\cdot 10^3\n$$\nThe goal is to solve for the fraction of infected hepatocytes, $f$. We can isolate $f$ by dividing both sides by $H p$:\n$$\nf = \\frac{c C_s V_p \\cdot 10^3}{H p}\n$$\nNow, we substitute the given numerical values into this expression:\n- $c = 0.70$ day$^{-1}$\n- $C_s = 1.5 \\times 10^{7}$ copies/mL\n- $V_p = 3.0$ L\n- $H = 2.5 \\times 10^{11}$ cells\n- $p = 1.0 \\times 10^{3}$ virions/(cell $\\cdot$ day)\n\n$$\nf = \\frac{(0.70) \\cdot (1.5 \\times 10^{7}) \\cdot (3.0) \\cdot 10^3}{(2.5 \\times 10^{11}) \\cdot (1.0 \\times 10^{3})}\n$$\nWe calculate the numerator and the denominator separately.\nNumerator:\n$$\n(0.70) \\cdot (1.5 \\times 10^{7}) \\cdot (3.0) \\cdot 10^3 = (0.70 \\cdot 1.5 \\cdot 3.0) \\times 10^{7+3} = 3.15 \\times 10^{10}\n$$\nDenominator:\n$$\n(2.5 \\times 10^{11}) \\cdot (1.0 \\times 10^{3}) = (2.5 \\cdot 1.0) \\times 10^{11+3} = 2.5 \\times 10^{14}\n$$\nNow, we perform the division:\n$$\nf = \\frac{3.15 \\times 10^{10}}{2.5 \\times 10^{14}} = \\frac{3.15}{2.5} \\times 10^{10-14} = 1.26 \\times 10^{-4}\n$$\nThe problem asks for the result to be expressed as a unitless decimal fraction rounded to three significant figures. The calculated value $1.26 \\times 10^{-4}$ already has three significant figures. As a decimal fraction, this is:\n$$\nf = 0.000126\n$$\nThis is the required fraction of infected hepatocytes to maintain the observed steady-state viral load.",
            "answer": "$$\n\\boxed{0.000126}\n$$"
        }
    ]
}